{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:45:19Z","timestamp":1769021119785,"version":"3.49.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1097\/md.0000000000008176","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T16:39:49Z","timestamp":1508344789000},"page":"e8176","source":"Crossref","is-referenced-by-count":11,"title":["Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy"],"prefix":"10.1097","volume":"96","author":[{"given":"Se Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi-Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Ok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Mee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-37-20210226","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-37-20210226","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jtho.2016.01.012","article-title":"Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes?","volume":"11","author":"Bunn","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R3-37-20210226","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer","volume":"24","author":"O\u2019Brien","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-37-20210226","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/01.JTO.0000263720.15062.51","article-title":"Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline","volume":"2","author":"Cheng","year":"2007","journal-title":"J Thorac Oncol"},{"key":"R5-37-20210226","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1200\/JCO.2003.09.130","article-title":"Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597","volume":"21","author":"Masters","year":"2003","journal-title":"J Clin Oncol"},{"key":"R6-37-20210226","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0093-7754(01)90075-2","article-title":"New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer","volume":"28","author":"Ettinger","year":"2001","journal-title":"Semin Oncol"},{"key":"R7-37-20210226","doi-asserted-by":"crossref","first-page":"156S","DOI":"10.1378\/chest.117.4_suppl_1.156S","article-title":"New chemotherapy agents for small cell lung cancer","volume":"117","author":"Kelly","year":"2000","journal-title":"Chest"},{"key":"R8-37-20210226","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lungcan.2003.10.003","article-title":"Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer","volume":"44","author":"Ando","year":"2004","journal-title":"Lung Cancer"},{"key":"R9-37-20210226","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/ijc.22984","article-title":"Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer","volume":"121","author":"Fennell","year":"2007","journal-title":"Int J Cancer"},{"key":"R10-37-20210226","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1200\/JCO.2008.18.1974","article-title":"Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402","volume":"26","author":"Inoue","year":"2008","journal-title":"J Clin Oncol"},{"key":"R11-37-20210226","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1200\/JCO.2010.29.8851","article-title":"Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy","volume":"29","author":"Jotte","year":"2011","journal-title":"J Clin Oncol"},{"key":"R12-37-20210226","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J Clin Oncol"},{"key":"R13-37-20210226","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.1995.13.6.1430","article-title":"Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study","volume":"13","author":"Ettinger","year":"1995","journal-title":"J Clin Oncol"},{"key":"R14-37-20210226","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00000421-199910000-00019","article-title":"Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group","volume":"22","author":"Kirschling","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"R15-37-20210226","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/bjc.1998.54","article-title":"A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer","volume":"77","author":"Smit","year":"1998","journal-title":"Br J Cancer"},{"key":"R16-37-20210226","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1200\/JCO.2001.19.5.1320","article-title":"Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Francais de Pneumo-Cancerologie study","volume":"19","author":"Thomas","year":"2001","journal-title":"J Clin Oncol"},{"key":"R17-37-20210226","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/jnci\/djg017","article-title":"Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer","volume":"95","author":"Reck","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R18-37-20210226","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1200\/JCO.2005.09.071","article-title":"Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732","volume":"23","author":"Niell","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-37-20210226","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.1999.17.3.927","article-title":"Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule","volume":"17","author":"Groen","year":"1999","journal-title":"J Clin Oncol"},{"key":"R20-37-20210226","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R21-37-20210226","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2307\/2530454","article-title":"Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis","volume":"38","author":"Anderson","year":"1982","journal-title":"Biometrics"},{"key":"R22-37-20210226","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2009.26.7682","article-title":"Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer","volume":"28","author":"Ettinger","year":"2010","journal-title":"J Clin Oncol"},{"key":"R23-37-20210226","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/1097-0142(19930815)72:4<1184::AID-CNCR2820720409>3.0.CO;2-Y","article-title":"Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base","volume":"72","author":"Albain","year":"1993","journal-title":"Cancer"},{"key":"R24-37-20210226","first-page":"777","article-title":"Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer","volume":"26","author":"Yamamoto","year":"2006","journal-title":"Anticancer Res"},{"key":"R25-37-20210226","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.1994.55","article-title":"Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro","volume":"69","author":"Jekunen","year":"1994","journal-title":"Br J Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:35:07Z","timestamp":1620959707000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201710200-00037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":25,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008176","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}